Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Common Shares, Warrants and Options (Details)	6 Months Ended
Common Shares, Warrants and Options (Details)	Feb. 28, 2023 $ / shares shares
Common Shares, Warrants and Options
Number of Warrants, Beginning Balance \| shares	2,421,983
Number of Warrants, Cancelled/Expired \| shares	(7,500)
Number of Warrants, Ending Balance \| shares	2,414,483
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 8.04
Weighted Average Exercise Price, Cancelled/Expired \| $ / shares	24.00
Weighted Average Exercise Price, Ending Balances \| $ / shares	$ 7.99